share_log

NeurAxis Announces New Medical Policy Coverage in North Dakota

NeurAxis Announces New Medical Policy Coverage in North Dakota

Neuraxis宣佈在北達科他州提供新的醫療保險
GlobeNewswire ·  04/23 21:00

CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the publication of medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), effective 05/06/2024, with a Blue Cross Blue Shield (BCBS) licensee in North Dakota. The BCBS licensee is the largest provider of health care coverage in North Dakota, insuring and/or administering claims for over 310,000 people, effective May 6, 2024.

印第安納州卡梅爾,2024年4月23日(GLOBE NEWSWIRE)——將針對兒童和成人慢性和虛弱性疾病的神經調節療法商業化的醫療技術公司NeuRaxis公司(“NeuRaxis” 或 “公司”)(紐約證券交易所美國股票代碼:NRXS)今天宣佈公佈經皮神經電場刺激(PENFS)的醫療保單,自2024年6月5日起生效,藍色北達科他州的Cross Blue Shield(BCBS)被許可人。BCBS被許可方是北達科他州最大的醫療保險提供商,自2024年5月6日起爲超過31萬人提供保險和/或管理索賠。

IB-Stim is a non-surgical device that sends gentle electrical impulses into cranial nerve bundles in the ear. Neuraxis' PENFS technology is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. There are currently no FDA-approved drug therapies for children with abdominal pain-related disorders of the gut-brain interaction. The current medical treatments, which are off-label drugs, can often have serious side effects, and most lack scientific evidence of efficacy.

ib-stim 是一種非手術設備,可將溫和的電脈衝發送到耳朵的腦神經束中。Neuraxis的PENFS技術已獲得美國食品藥品管理局的批准,用於治療11-18歲青少年的與腸易激綜合症(IBS)相關的功能性腹痛。目前沒有經美國食品藥品管理局批准的用於患有腹痛相關腸腦相互作用障礙的兒童的藥物療法。目前的藥物是非標籤藥物,通常會產生嚴重的副作用,而且大多數缺乏療效的科學證據。

"We are pleased to announce a new medical coverage policy, expanding our total covered lives for IB-Stim to approximately 16.5 million individuals, which speaks to the strength of the clinical data," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "We remain focused on executing on our commercial strategy, leveraging strong clinical evidence to obtain payer coverage and drive market adoption of our technology. We look forward to receiving additional coverage from payers on a national level."

NeurAxis總裁兼首席執行官布萊恩·卡里科表示:“我們很高興地宣佈一項新的醫療保險政策,將我們的IB-STIM的總承保壽命擴大到約1,650萬人,這說明了臨床數據的力量。”“我們仍然專注於執行我們的商業戰略,利用有力的臨床證據來獲得付款人的保障,推動我們的技術在市場上的採用。我們期待在全國範圍內從付款人那裏獲得更多保險。”

About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit and

關於 NeurAxis, Inc.
NeurAxis, Inc. 是一家醫療技術公司,專注於神經調節療法,以解決兒童和成人的慢性和虛弱性疾病。Neuraxis致力於推動科學發展,利用循證醫學推動醫學、科學界和患者界採用其IB-STIM療法,即其專有的經皮神經電場刺激(PENFS)技術。IB-Stim已獲美國食品藥品管理局批准,用於治療11-18歲青少年的與腸易激綜合徵(IBS)相關的功能性腹痛。PENFS在多種未得到滿足的醫療需求的兒科和成人疾病中進行的其他臨床試驗正在進行中。欲了解更多信息,請訪問和

Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company's stock, public health issues or other events, the Company's compliance with applicable laws, the results of the Company's clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis's public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.

前瞻性陳述
本新聞稿中的某些陳述是經修訂的1933年《證券法》第27A條和經修訂的1934年《證券交易法》第21E條所指的前瞻性陳述。除歷史事實陳述以外的所有陳述均爲前瞻性陳述。前瞻性陳述基於管理層當前對未來事件和趨勢的假設和預期,這些事件和趨勢會影響或可能影響公司的業務、戰略、運營或財務業績,由於存在許多風險和不確定性,實際業績和其他事件可能與此類陳述中表達或暗示的重大差異。前瞻性陳述本質上受風險和不確定性的影響,其中一些風險和不確定性無法預測或量化。有許多重要因素可能導致實際業績、發展、商業決策或其他事件與本新聞稿中前瞻性陳述所設想的重大差異。除其他外,這些因素包括美國和全球經濟狀況、公司股票的交易價格和波動性、公共衛生問題或其他事件、公司對適用法律的遵守情況、公司臨床試驗的結果及其看法、向美國食品藥品管理局提交報告的結果、允許發行優先股的股東投票結果以及Neuraxis向美國提交的公開文件風險因素部分中描述的因素證券交易委員會(SEC)。由於前瞻性陳述本質上受風險和不確定性的影響,因此您不應依賴這些前瞻性陳述作爲對未來事件的預測。這些前瞻性陳述僅代表截至本新聞稿發佈之日,除非適用法律要求,否則公司沒有義務更新或修改這些陳述,無論是由於任何新信息、未來事件和發展還是其他原因。

Contacts:

聯繫人:

Company
NeurAxis, Inc.
info@neuraxis.com

公司
NeurAxis, Inc.
info@neuraxis.com

Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com

投資者關係
萊瑟姆合作伙伴
本·沙姆西安
646-829-9701
shamsian@lythampartners.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論